@article{oai:yamanashi.repo.nii.ac.jp:00003196,
 author = {YAMAMOTO, Yasuyoshi and IIZUKA, Hidehiko and YAMAMOTO, Masayuki and TASAKA, Kachio and SUGAHARA, Katsuhiko},
 issue = {1},
 journal = {山梨医科大学雑誌, 山梨医科大学雑誌},
 month = {},
 note = {We performed immunochemotherapy using a continuous infusion of recombinant interleukin 2 (IL2) and intermittent one-shot-injections of Adriamycin (ADR) administered directly to the hepatic artery in 6 cases of advanced hepatocellular carcinoma (HCC). Although the observation periods were short, the tumors reduced in size; most notably, a massive tumor in the right lobe disappeared in one case. After reviewing the 6 patients with HCC, we demonstrated a possible cause of ADR as a kind of immuno-modifier. In an in vitro study, the susceptibility of subpopulations of lymphocytes to ADR was variable with the suppressor T cell being more susceptible to ADR compared to the helper T cell. In HCC patients, the ratio of the suppressor T cells to the helper T cells (suppressor/helper ratio) was significantly higher than that of the healthy controls. Thus, following the administration of the optimal dose of ADR, specific decrease in the suppressor T cell and increase in the helper T cell in response to ADR can be obtained for the recovery of the suppressor/helper ratio. Moreover, ADR-treated lymphocytes of HCC patients exhibited constant killer activity in the presence of IL2. Although the optimal dose of ADR for clinical use may be within a very narrow range, ADR combined with IL2 following tumor mass-reduction treatments may restore the immunity of advanced HCC patients and prolong their survival.},
 pages = {25--34},
 title = {<Original Article> A Proposal of Effctive Immunochemotherapy Using Recombinant Interleukin 2 and Adriamycin, and Its Theoretical Background},
 volume = {5},
 year = {1990}
}